NCT03841617 2026-02-17
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT06980103 2026-01-08
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
Georgetown University
Phase NA Recruiting
NCT00673010 2025-10-09
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03215095 2025-07-17
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05142904 2025-07-17
RABITO
Rijnstate Hospital
Phase 3 Terminated